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   Introduction 
Conventionally, the time between diagnosis and date of last follow up or death is used 
to plot survival curves for patients with cancer. This ignores the patient's expected life 
span had the patient been healthy at the time of diagnosis. In human terms the impact 
of a projected prognosis of 10 year survival on a woman diagnosed as having breast 
cancer, for example, may be different depending on whether she is aged 30 or 70. 
Furthermore, oncologists have no answer to the question: "What is my chance of 
cure?" For this reason, we believe that survival is better expressed as a fraction of 
normal remaining life span expected at the time of diagnosis. We propose a new 
method which takes account of age at diagnosis in calculating survival.   
 
 
   The new method 
To illustrate this concept we used a database of 1134 patients with breast cancer from 
Bombay who were operated on at Tata Memorial Hospital between 1974 and 1988. 
The patients were divided into three groups on the basis of the number of involved 
axillary lymph nodes (0, 1-4, and >4). The survival curves were plotted in two 
different ways: by the conventional method (fig 1) and by a new way that we call the 
real life expectancy method (fig  2). The difference in the two methods is not in the 
statistical handling of data but in the way period of survival is expressed. Both curves 
were plotted with the computer program SUREAL by the actuarial method.1  
 
 
 
 
   
Fig 1 Conventional 
actuarial survival 
curves, with x axis 
indicating number 
of years from 
diagnosis and y 
axis indicating 
cumulative 
percentage 
surviving  
 
 
 
 
Fig 2 Real life 
expectancy curves, 
with x axis 
indicating fraction 
of normal 
remaining life and 
y axis indicating 
cumulative 
percentage 
surviving  
 
To plot real life expectancy curves we used data from the Life Insurance Corporation 
of India to estimate the normal life expectancy of each patient at the age of diagnosis 
had she not had breast cancer (Life Insurance Corporation of India, personal 
communication). At the time of survival analysis each patient's age at diagnosis was 
subtracted form her normal life expectancy at that age to obtain what we call normal 
remaining life (NRL). The time from diagnosis to the date of last follow up or death 
was then calculated and divided by the normal remaining life to obtain the percentage 
of normal remaining life that had been lived by the patient. For example, in India, a 
healthy woman of 40 woman has a normal life expectancy of 72 years and a normal 
remaining life (NRL) of 32 years (72-40). If at 40 she were diagnosed as having breast 
cancer and she lived for 10 years her survival is expressed as 31% of her normal 
remaining life (10/32x100). On the other hand, a patient who is diagnosed as having 
breast cancer at 60 would have a normal life expectancy of 75 years and normal 
remaining life (NRL) of 15 years (75-60). If she lives for 10 years after diagnosis her 
survival is expressed as 67% (10/15x100) of her normal remaining life. To plot the 
real life expectancy curves we used these percentage figures instead of actual number 
of years. The mathematical procedure and statistical considerations are exactly the 
same as that used for plotting conventional actuarial survival curves. The difference is 
that survival time, instead of being expressed as years from diagnosis, is expressed as 
percentage of the remaining life which the woman would have lived had she been 
healthy. Thus, to plot real life expectancy curves we convert the years from diagnosis 
to percentage of normal remaining life, and to use these curves to calculate survival 
for an individual patient we convert the percentage figure back into number of years, 
calculated according to each patient's normal life expectancy (see below). The 
percentage figures may be used to compare different groups of patients.  
 
 
Summary points 
Conventional survival curves for cancer use the time between diagnosis and last 
follow up or death to denote survival time 
This ignores a person's normally expected life span at the age of diagnosis and 
estimates survival in terms of a fixed number of years 
Our new method proposes that each patient's age at diagnosis is subtracted from 
the average life expectancy for that age to obtain the patient's normal remaining 
life (NRL) 
At analysis the percentage of normal remaining life that has been lived by the 
patient is calculated and used in place of survival time to plot actuarial survival 
curves 
An estimate of survival time, which will vary with age at diagnosis, can then be 
calculated for each individual patient 
Survival expressed as a probability of living a fraction of normal life span gives a 
better idea than conventional methods of the impact of a disease such as cancer 
on an individual patient's life 
Oncologists can now answer the unanswerable: "What is the chance of my 
`cure'?" 
 
 
 
 
 
  Comparison between conventional and real life 
expectancy method 
According to the conventional survival curves given in figure 1), the 5 year survival of 
node negative, 1-4 node positive, >4 node positive patients is 88%, 66%, and 40% 
respectively. According to the real life expectancy curves given in figure 2), one fifth 
normal remaining life survival of these three groups of patients is 89%, 65%, and 38% 
respectively. Just as survival estimates for any number of years can be read off from 
the conventional curves survival estimates for any fraction of normal remaining life 
can be read off from real life expectancy curves. Instead of the conventional 5 year or 
10 year survival we say survival for a fifth or half of normal remaining life (1/5 NRL 
or ½ NRL), or even for full normal remaining life (cure). As normal remaining life 
changes with age, an individual patient's survival estimate (in years from diagnosis) 
will also change with age.  
On the basis of conventional life table curves shown in figure 1), a node negative 
woman has an 82% chance of living for 10 years. With the real life expectancy curves 
(fig 2) she has a 81% chance of living half of her normal remaining life. As the normal 
life expectancy of a 40 year old Indian woman is 72 years and that of a 60 year old 
woman 75 years, this would  work out to a 81% chance of living for 16 years ((72-
40)/2) for a woman of 40 and an 81% chance of living for 7.5 years ((75-60)/2) for a 
woman of 60. With these new curves, we could even say that a node negative woman 
has a 68% chance of living her full normal remaining life, which is 32 years (72-40) 
for a 40 year old woman and 15 years (75-60) for a 60 year old woman. A similar 
difference in the estimates by the conventional and real life expectancy curves is seen 
for the two other lymph node groups (table 1).  
Table 1 Comparison of survival estimates by conventional and real life expectancy methods  
 
Conventional 
method Real life expectancy method 
 
Node negative;  
88% Survive 5 years 89% Survive a fifth of normal remaining life (6.4 years at age 40, 3 years at age 
60) 
82% Survive 10 years 81% Survive half normal remaining life (16 years at 40, 7.5 years at 60) 
 68% Survive full normal remaining life (cure) (32 years at 40, 15 years at 60) 
1-4 Nodes positive  
66% Survive 5 years 65% Survive a fifth normal remaining life (6.4 years at 40, 3 years at 60) 
48% Survive 10 years 38% Survive half normal remaining life (16 years at 40, 7.5 years at 60) 
 28% Survive full normal remaining life (cure) (32 years at 40, 15 years at 60) 
>4 Nodes positive  
40% Survive 5 years 38% Survive a fifth normal remaining life (6.4 years at 40, 3 years at 60) 
22% Survive 10 years 20% Survive a half normal remaining life (16 years at 40, 7.5 years at 60) 
 None survive full normal remaining life (cure)  
 
  
  
  Fundamental change in perspective 
Living all of normal remaining life is equivalent to cure. It could be said that node 
negative women have a 68% chance of being cured of breast cancer. The importance 
of the facility to express survival in terms of cure, especially for a disease such as 
cancer, is profound. This might help to resolve the controversy about whether some 
chronic diseases such as breast cancer are ever cured.2  
Once adulthood is attained life expectancy does not change greatly with age. For 
example, for an Indian population it is 71 years for those aged 15-30, 72 years for 
those aged 31-45, 75 for those aged 57-60, and 80 for those aged 71-72, and so on. 
What does change with age, however, is the remaining life expected to be lived 
(normal remaining life) and, consequently, the percentage of remaining life actually 
lived by the patient. For a 40 year old woman normal remaining life is 32 years (72-
40), whereas for a 60 year old woman it is 15 years (75-60). Since the average life 
expectancy changes little once adulthood is attained and since we express survival in 
terms of fractions of normal remaining life rather than in absolute number of years, a 
substantial interclass (social) or intercountry variation should not occur in our 
estimates of survival. Of course, the study population should be reasonably similar to 
the population whose normal life expectancy is used for the calculations.  
Survival of patients with various diseases may be compared with that of the normal 
population by other methods.3 4 5 6 7 8 Unlike our method, these methods usually 
require cumbersome calculations. Typically, they compare two survival curves, one 
for the general and the other for the diseased population, and they may include 95% 
confidence limits.2 This does not lend itself to easy translation in terms of individual 
estimates of life span or cure rates, especially by someone with little statistical 
knowledge such as a clinician or patient. The advantage of our method is that the 
comparison between the normal population and patients with disease is integrated in a 
single curve that is similar to the conventional survival curves except for the label 
given in the x axis. Our method is not intended to replace the expression of survival as 
a yearly probability relative to the general population6 as this has a different purpose 
of elucidating the temporal biology of the disease.  
There are two additional steps in our method. Firstly, the calculations use actuarial life 
tables for normal life expectancy. This can be easily integrated as a simple arithmetic 
formula in the database. Secondly, to translate the fraction of normal remaining life to 
actual number of years for an individual patient requires the use of life expectancy 
tables. This is facilitated by using a table such as table 1.  
Our new method is not a new statistical procedure but introduces a subtle change in 
the perspective of the standard method. When survival is expressed in the manner we 
describe, the impact of a potentially lethal disease on an individual patient's life, 
especially when the disease is prevalent across a broad range of ages, is more 
meaningfully defined. We believe that it is kinder to a patient with breast cancer, for 
example, to estimate her survival in terms of the whole life span rather than to limit it 
to five or 10 years. We believe that by individualising survival estimates according to 
age and expressing survival in terms of cure rates the new method that we have 
proposed makes survival estimates more meaningful, relevant, and human.  
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